Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Conditions: HIV Infections
Interventions: CAB LA, RPV LA, RPV, DTG; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more

Conditions: HIV Infections
Interventions: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 16
States / cities: San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hiv
Interventions: Collaborative drug therapy management model, Cabotegravir/Rilpivirine; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: CAB-RPV LA, Standard treatment within an HIV clinic; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections, Opioid Use, Trauma, Psychological
Interventions: Not listed
Lead sponsor: Alexis Roth; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: APRETUDE, Cabotegravir tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more

Conditions: HIV Treatment, HIV Prevention
Interventions: At Home Self-Collections; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Infection, Human Immunodeficiency Virus
Interventions: CAB, RIF; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: CAB LA+RPV LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more

Conditions: HIV
Interventions: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM), HIV Stigma Scale Questionnaire, HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12), HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12), Needs and Barriers Assessment, Pre-visit Outreach, Qualitative interview - patient participants, Staff education, Staff Month 7 and 15 Survey - Staff Burden and Engagement, Qualitative interview - staff; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: HIV Infections
Interventions: Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, Standard of Care (SOC) ART; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: HIV-1-infection
Interventions: Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Memphis, Tennessee

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,049 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more

Conditions: HIV, Prophylaxis, Injectable
Interventions: Cabotegravir Injectable Suspension (CAB LA); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 19 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: HIV Infections
Interventions: DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more

Conditions: HIV Infections
Interventions: CAB LA, New formulation of CAB LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more

Search by objective public record fields.

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Improving Treatment and Retention Adherence in Nontraditional Settings

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Cabotegravir-Hormone PK/PD Interactions for HIV Prevention

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)